Aligos Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aligos Therapeutics, Inc. (ALGS) on August 8, 2024, reporting events occurring on August 7, 2024. The Company is a Delaware corporation listed on the Nasdaq Capital Market and is classified as an emerging growth company.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
Effective August 7, 2024, the Board of Directors increased the number of authorized directors from six to seven. Two new directors were appointed to fill the newly created seats:
- Heather Preston, M.D.: Appointed as a Class II director. She will serve as a member and the chair of the Nominating Committee.
- Margarita Chavez, J.D.: Appointed as a Class II director. She will serve on the Audit Committee.
Both directors have terms expiring at the 2025 annual meeting of stockholders.
Compensation and Governance Details
Pursuant to the Company's non-employee director compensation program, the new directors received the following compensation packages (prorated for the remainder of 2024):
- Annual Retainer: $40,000 for Board service.
- Equity Grant: Automatic initial grant of stock options to purchase 120,000 shares of Common Stock under the 2020 Incentive Award Plan.
- Committee Fees:
- Dr. Preston: $8,000 annual additional cash compensation for chairing the Nominating Committee.
- Ms. Chavez: $7,500 annual additional cash compensation for serving on the Audit Committee.
Both directors entered into the Company's standard indemnification agreement. No relationships requiring disclosure under Item 404(a) of Regulation S-K were identified.
Investor Verification Checklist
- Verify the exact prorated cash compensation amounts for 2024 based on the August 7 start date.
- Review the terms of the stock option grants (exercise price, vesting schedule) in the Company's 2020 Incentive Award Plan.
- Confirm the updated Board composition and committee assignments in subsequent filings.
- Check the Company's most recent Form 10-Q (filed August 6, 2024) for the full text of the non-employee director compensation program referenced in this filing.